The predominant forms of drug delivery (oral and parenteral) benefit from significant convenience and other advantages. However, systemic delivery is often impacted by such factors as first-pass metabolism, off-target activity, unwanted or dose limiting side effects, a reliance on passive drug uptake, and sub-therapeutic drug levels.
In diseases where the precise and targeted delivery of therapeutics is important, and off-target side effects significant, systemic approaches have clear shortcomings.
Focal Medical is taking targeted therapeutics in revolutionary new directions. Using an electrical field, we can ensure active, precise, and targeted drug delivery at higher concentrations in target cells than is achievable by systemic administration, with dramatically lower systemic exposure and associated side effects.
Focal Medical can tune and modulate certain parameters of its system to optimize the active delivery of molecules into target cells using non-blood pathways, ensuring even poorly vascularized organs and tissues receive drug therapy.
Our iontophoretic system uses electrical current to actively drive drugs directly into target cells. Under the influence of a mild electric field, drug molecules exit the device through a semi-permeable membrane and are actively transported into the target cells in the electric field.
Our technology co-ops non-circulatory pathways to transit tissue and penetrate cells and thus overcomes both delivery barriers and drug degradation issues. By delivering the drug specifically to the cellular matrix, subjects tolerate the increased concentration of drug necessary to achieve an optimal therapeutic effect.
Our system is highly tunable. We can modulate various control parameters (including current, voltage, time, and drug concentration) to optimize drug delivery performance.